These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 33860598)

  • 1. Materials for Improving Immune Cell Transfection.
    Kumar ARK; Shou Y; Chan B; L K; Tay A
    Adv Mater; 2021 May; 33(21):e2007421. PubMed ID: 33860598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Automating CAR-T Transfection with Micro and Nano-Technologies.
    Hu T; Kumar AR; Luo Y; Tay A
    Small Methods; 2024 Aug; 8(8):e2301300. PubMed ID: 38054597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomaterials in Chimeric Antigen Receptor T-Cell Process Development.
    Cardle II; Cheng EL; Jensen MC; Pun SH
    Acc Chem Res; 2020 Sep; 53(9):1724-1738. PubMed ID: 32786336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a microfluidic cell transfection device into gene-edited CAR T cell manufacturing workflow.
    Yu T; Jhita N; Shankles P; Fedanov A; Kramer N; Raikar SS; Sulchek T
    Lab Chip; 2023 Nov; 23(22):4804-4820. PubMed ID: 37830228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimized Production of Lentiviral Vectors for CAR-T Cell.
    Moço PD; de Abreu Neto MS; Fantacini DMC; Picanço-Castro V
    Methods Mol Biol; 2020; 2086():69-76. PubMed ID: 31707668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanotechnology and immunoengineering: How nanotechnology can boost CAR-T therapy.
    Nawaz W; Xu S; Li Y; Huang B; Wu X; Wu Z
    Acta Biomater; 2020 Jun; 109():21-36. PubMed ID: 32294554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing Transfection Efficiency in CAR-T Cell Manufacturing through Multiple Administrations of Lipid-Based Nanoparticles.
    Giulimondi F; Digiacomo L; Renzi S; Cassone C; Pirrottina A; Molfetta R; Palamà IE; Maiorano G; Gigli G; Amenitsch H; Pozzi D; Zingoni A; Caracciolo G
    ACS Appl Bio Mater; 2024 Jun; 7(6):3746-3757. PubMed ID: 38775109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Self-Assembled Nanoparticles Prepared from Low-Molecular-Weight PEI and Low-Generation PAMAM for EGFRvIII-Chimeric Antigen Receptor Gene Loading and T-Cell Transient Modification.
    Yu Q; Zhang M; Chen Y; Chen X; Shi S; Sun K; Ye R; Zheng Y; Chen Y; Xu Y; Peng J
    Int J Nanomedicine; 2020; 15():483-495. PubMed ID: 32158206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Vitro-Transcribed (IVT)-mRNA CAR Therapy Development.
    Miliotou AN; Papadopoulou LC
    Methods Mol Biol; 2020; 2086():87-117. PubMed ID: 31707670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and Validation of a Good Manufacturing Process for IL-4-Driven Expansion of Chimeric Cytokine Receptor-Expressing CAR T-Cells.
    van Schalkwyk MCI; van der Stegen SJC; Bosshard-Carter L; Graves H; Papa S; Parente-Pereira AC; Farzaneh F; Fisher CD; Hope A; Adami A; Maher J
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigen Presenting Cell Mimetic Lipid Nanoparticles for Rapid mRNA CAR T Cell Cancer Immunotherapy.
    Metzloff AE; Padilla MS; Gong N; Billingsley MM; Han X; Merolle M; Mai D; Figueroa-Espada CG; Thatte AS; Haley RM; Mukalel AJ; Hamilton AG; Alameh MG; Weissman D; Sheppard NC; June CH; Mitchell MJ
    Adv Mater; 2024 Jun; 36(26):e2313226. PubMed ID: 38419362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy.
    Ghassemi S; Milone MC
    J Vis Exp; 2019 Dec; (154):. PubMed ID: 31904011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells.
    Hu B; Zou Y; Zhang L; Tang J; Niedermann G; Firat E; Huang X; Zhu X
    Hum Gene Ther; 2019 Apr; 30(4):446-458. PubMed ID: 29706119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanomaterials to improve cancer immunotherapy based on ex vivo engineered T cells and NK cells.
    Han B; Song Y; Park J; Doh J
    J Control Release; 2022 Mar; 343():379-391. PubMed ID: 35124129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution of the clinical-stage hyperactive TcBuster transposase as a platform for robust non-viral production of adoptive cellular therapies.
    Skeate JG; Pomeroy EJ; Slipek NJ; Jones BJ; Wick BJ; Chang JW; Lahr WS; Stelljes EM; Patrinostro X; Barnes B; Zarecki T; Krueger JB; Bridge JE; Robbins GM; McCormick MD; Leerar JR; Wenzel KT; Hornberger KM; Walker K; Smedley D; Largaespada DA; Otto N; Webber BR; Moriarity BS
    Mol Ther; 2024 Jun; 32(6):1817-1834. PubMed ID: 38627969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma.
    Brown CE; Aguilar B; Starr R; Yang X; Chang WC; Weng L; Chang B; Sarkissian A; Brito A; Sanchez JF; Ostberg JR; D'Apuzzo M; Badie B; Barish ME; Forman SJ
    Mol Ther; 2018 Jan; 26(1):31-44. PubMed ID: 29103912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of CAR-T cells using lentiviral vectors.
    Poorebrahim M; Quiros-Fernandez I; Fakhr E; Cid-Arregui A
    Methods Cell Biol; 2022; 167():39-69. PubMed ID: 35152998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity.
    Yu S; Yi M; Qin S; Wu K
    Mol Cancer; 2019 Aug; 18(1):125. PubMed ID: 31429760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minicircle-Based Engineering of Chimeric Antigen Receptor (CAR) T Cells.
    Hudecek M; Gogishvili T; Monjezi R; Wegner J; Shankar R; Kruesemann C; Miskey C; Ivics Z; Schmeer M; Schleef M
    Recent Results Cancer Res; 2016; 209():37-50. PubMed ID: 28101686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
    Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.